CN101130030B - Medicine composition for treating nephropathy and uses of the same - Google Patents

Medicine composition for treating nephropathy and uses of the same Download PDF

Info

Publication number
CN101130030B
CN101130030B CN2007101205085A CN200710120508A CN101130030B CN 101130030 B CN101130030 B CN 101130030B CN 2007101205085 A CN2007101205085 A CN 2007101205085A CN 200710120508 A CN200710120508 A CN 200710120508A CN 101130030 B CN101130030 B CN 101130030B
Authority
CN
China
Prior art keywords
weight portion
weight
radix
portions
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007101205085A
Other languages
Chinese (zh)
Other versions
CN101130030A (en
Inventor
闫位国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2007101205085A priority Critical patent/CN101130030B/en
Publication of CN101130030A publication Critical patent/CN101130030A/en
Application granted granted Critical
Publication of CN101130030B publication Critical patent/CN101130030B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a pharmaceutical composition for treating nephritis, which comprises 35 kinds of Chinese herbs including croton, piper nigrum, dried orange peel, banksia rose, licorice root, achyranthes and cyathula root, prepared aconite root, mirabilite and rhubarb horsetails.

Description

A kind of pharmaceutical composition and application thereof for the treatment of nephropathy
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of nephropathy and preparation method thereof.
Background technology
Nephritis (edema) is a kind of heart failure that mainly causes, renal failure, and lung declines, the lethal commonly encountered diseases of uremia; edema is because of water retention in the body, spreads unchecked skin and causes women's head-ornaments, eye, face; extremity, the abdomen back of the body even anasarca are a class disease of feature, weight person can be with hydrothorax and ascites; the acute and chronic glomerulonephritis, the nephrotic syndrome, congestive heart failure; endocrine disturbance and malnutrition etc., exopathogen invasion and attack, the not normal or overstrain internal injury of daily life; cause the obstructed accent of lung, spleen loses and transfers, and kidney loses folding; have no right to functioning of bladder eventually, the three warmers water channel loses smooth, and water liquid stops gathering; spread unchecked skin and become edema, spread unchecked in the edema disease edema due to wind pathogen, the sore contamination; the wet dipping of water, damp and hot heap soil or fertilizer over and around the roots is contained, and the spleen sun is on the decline; the all cards of kidney yang deficiency, therefore, YANG edema; YIN edema belongs to the severe pathogenic cold disease, causes acute and chronic nephritis, the nephrotic syndrome; uremia worsens into heart failure, lung renal failure etc.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition for the treatment of nephritis.
Another purpose of the present invention is to provide this preparation of drug combination method.
Another purpose of the present invention also is to provide the purposes of this pharmaceutical composition.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
A group: Fructus Crotonis 15-45 weight portion Fructus Piperis 3-7 weight portion Pericarpium Citri Reticulatae 3-7 weight portion
Radix Aucklandiae 3-7 weight portion Radix Glycyrrhizae 3-7 weight portion Radix Achyranthis Bidentatae 15-45 weight portion
B group: Radix Aconiti Lateralis Preparata 70-200 weight portion Natrii Sulfas 12-38 weight portion Radix Et Rhizoma Rhei 30-90 weight portion
Concha Ostreae 50-150 weight portion
C group: Rhizoma Atractylodis Macrocephalae 7-23 weight portion Poria 25-65 weight portion Cortex Cinnamomi 10-30 weight portion
Radix Paeoniae Alba 5-15 weight portion Rhizoma Zingiberis 20-60 weight portion Polyporus 15-45 weight portion
Herba Leonuri 15-45 weight portion Rhizoma Imperatae 25-75 weight portion Rhizoma Alismatis 25-75 weight portion
Fructus Amomi 10-30 weight portion Herba Pyrolae 20-60 weight portion Rhizoma Zingiberis Recens 30-60 weight portion
Ramulus Cinnamomi 10-30 weight portion Radix Glycyrrhizae 2-8 weight portion Radix Morindae Officinalis 10-30 weight portion
Semen Cuscutae 10-30 weight portion Herba Epimedii 10-30 weight portion Fructus Amomi Rotundus 10-30 weight portion
Radix Astragali 30-90 weight portion Rhizoma Atractylodis 10-30 weight portion Fructus Corni 50-150 weight portion
Radix Angelicae Sinensis 15-45 weight portion Pericarpium Arecae 15-45 weight portion Cortex Magnoliae Officinalis 5-15 weight portion
Herba Lysimachiae 15-45 weight portion
The crude drug composition of pharmaceutical composition of the present invention is preferably:
A group: Fructus Crotonis 29 weight portion Fructus Piperiss 5 weight portion Pericarpium Citri Reticulataes 5 weight portions
The Radix Aucklandiae 5 weight portion Radix Glycyrrhizaes 5 weight portion Radix Achyranthis Bidentataes 30 weight portions
B group: Radix Aconiti Lateralis Preparata 135 weight portion Natrii Sulfas 25 weight portion Radix Et Rhizoma Rhei 59 weight portions
Concha Ostreae 100 weight portions
C group: the Rhizoma Atractylodis Macrocephalae 15 weight portion Poria 45 weight portion Cortex Cinnamomis 20 weight portions
The Radix Paeoniae Alba 10 weight portion Rhizoma Zingiberiss 40 weight portion Polyporus 30 weight portions
Herba Leonuri 30 weight portion Rhizoma Imperataes 50 weight portion Rhizoma Alismatis 50 weight portions
Fructus Amomi 20 weight portion Herba Pyrolaes 40 weight portion Rhizoma Zingiberis Recenss 45 weight portions
Ramulus Cinnamomi 20 weight portion Radix Glycyrrhizaes 5 weight portion Radix Morindae Officinaliss 20 weight portions
Semen Cuscutae 20 weight portion Herba Epimedii 20 weight portion Fructus Amomi Rotunduss 20 weight portions
The Radix Astragali 60 weight portion Rhizoma Atractylodis 20 weight portion Fructus Corni 100 weight portions
Radix Angelicae Sinensis 30 weight portion Pericarpium Arecae 30 weight portion Cortex Magnoliae Officinalis 10 weight portions
Herba Lysimachiae 30 weight portions
The crude drug composition of pharmaceutical composition of the present invention is preferably:
A group: Fructus Crotonis 20 weight portion Fructus Piperiss 6 weight portion Pericarpium Citri Reticulataes 4 weight portions
The Radix Aucklandiae 6 weight portion Radix Glycyrrhizaes 4 weight portion Radix Achyranthis Bidentataes 40 weight portions
B group: Radix Aconiti Lateralis Preparata 100 weight portion Natrii Sulfas 35 weight portion Radix Et Rhizoma Rhei 40 weight portions
Concha Ostreae 130 weight portions
C group: the Rhizoma Atractylodis Macrocephalae 10 weight portion Poria 60 weight portion Cortex Cinnamomis 15 weight portions
The Radix Paeoniae Alba 13 weight portion Rhizoma Zingiberiss 25 weight portion Polyporus 40 weight portions
Herba Leonuri 20 weight portion Rhizoma Imperataes 70 weight portion Rhizoma Alismatis 30 weight portions
Fructus Amomi 25 weight portion Herba Pyrolaes 25 weight portion Rhizoma Zingiberis Recenss 55 weight portions
Ramulus Cinnamomi 15 weight portion Radix Glycyrrhizaes 6 weight portion Radix Morindae Officinaliss 15 weight portions
Semen Cuscutae 25 weight portion Herba Epimedii 15 weight portion Fructus Amomi Rotunduss 25 weight portions
The Radix Astragali 40 weight portion Rhizoma Atractylodis 25 weight portion Fructus Corni 70 weight portions
Radix Angelicae Sinensis 40 weight portion Pericarpium Arecae 20 weight portion Cortex Magnoliae Officinalis 13 weight portions
Herba Lysimachiae 20 weight portions
Drug regimen raw material composition of the present invention is preferably:
A group: Fructus Crotonis 40 weight portion Fructus Piperiss 4 weight portion Pericarpium Citri Reticulataes 6 weight portions
The Radix Aucklandiae 4 weight portion Radix Glycyrrhizaes 6 weight portion Radix Achyranthis Bidentataes 20 weight portions
B group: Radix Aconiti Lateralis Preparata 170 weight portion Natrii Sulfas 15 weight portion Radix Et Rhizoma Rhei 80 weight portions
Concha Ostreae 70 weight portions
C group: the Rhizoma Atractylodis Macrocephalae 20 weight portion Poria 30 weight portion Cortex Cinnamomis 25 weight portions
The Radix Paeoniae Alba 7 weight portion Rhizoma Zingiberiss 55 weight portion Polyporus 20 weight portions
Herba Leonuri 40 weight portion Rhizoma Imperataes 30 weight portion Rhizoma Alismatis 70 weight portions
Fructus Amomi 15 weight portion Herba Pyrolaes 55 weight portion Rhizoma Zingiberis Recenss 35 weight portions
Ramulus Cinnamomi 25 weight portion Radix Glycyrrhizaes 3 weight portion Radix Morindae Officinaliss 25 weight portions
Semen Cuscutae 15 weight portion Herba Epimedii 25 weight portion Fructus Amomi Rotunduss 15 weight portions
The Radix Astragali 80 weight portion Rhizoma Atractylodis 15 weight portion Fructus Corni 130 weight portions
Radix Angelicae Sinensis 20 weight portion Pericarpium Arecae 40 weight portion Cortex Magnoliae Officinalis 7 weight portions
Herba Lysimachiae 40 weight portions
Described Fructus Crotonis is preferably given birth to Fructus Crotonis, the preferred Radix Et Rhizoma Rhei of described Radix Et Rhizoma Rhei; The preferred Radix Glycyrrhizae of described Radix Glycyrrhizae, the preferred Radix Aconiti Lateralis Preparata of described Radix Aconiti Lateralis Preparata.
Preparation of drug combination method of the present invention is: A group, B group, C group medicine are ground into fine powder respectively, again with three groups of medicated powder mix homogeneously routinely technology add conventional adjuvant and make the tablet of clinical acceptance, capsule, granule or pill.
Pharmaceutical composition of the present invention adds the dosage form that conventional adjuvant is made clinical acceptance by practice of pharmacy, as tablet, capsule, granule, pill, oral liquid, lyophilized powder or drop pill etc.
Pharmaceutical composition of the present invention has drastic purgation to treat cold constipation, opens obturation, cleanses the intestines and stomach, controls cold syndrome of aversion to cold lasting day and night with cold limbs, the food stagnation that contracts stagnates, attacks the function that expectorant is satisfied wet, diuretic detumescent, relieving constipation diuretic, inducing diuresis to remove edema, removing severe pathogenic cold, regulated the QI and blood balance, can be fast that the wet eliminating of severe pathogenic cold water is external, recover body function, to the nephrotic syndrome uremia that causes of treatment nephritis (edema) cause that heart failure, renal failure, lung decline, abdominal distention ascites, dyspnea, oliguria or anuria etc. have remarkable result, and take safety, without any side effects.
Following experimental example and embodiment are used to further specify the present invention, but are not limited to the present invention.
Experimental example 1
Pharmaceutical composition of the present invention is example surplus clinical observation treatment nephritis (edema) patient 1000 in recent years, obtains remarkable result, now is reported as follows:
One, clinical data:
Medicine composite for curing nephritis of the present invention (edema) is example surplus in the of person-times 1000 in recent years, and the course of disease is the shortest 11 days, and is the longest 2 years, and wherein male's 650 examples account for 65%; Women's 100 examples account for 10%; Children's's 250 examples account for 25%; Minimum 6 years old of age, maximum 70 years old.
Two, diagnostic criteria
Clinical drug of the present invention is observed the patient and is made a definite diagnosis through County Hospital.
Two, Therapeutic Method
1000 routine patients all accept Drug therapy after a while in the outer court, but symptom can not control, and day increase the weight of then, take pill of the present invention, every day 1 time, each 1, every 9 gram, treatment time 7-30 days.
Three, criterion of therapeutical effect:
Recovery from illness: after the treatment, the recovery from illness of patient's symptom recovers normal;
Produce effects: after the treatment, sx;
Invalid: after the treatment, symptom does not have obvious change.
Four, result:
Pill treatment nephritis (edema) 1000 examples of the present invention, 950 examples of wherein fully recovering account for 95%, and 5 examples that take a turn for the better account for 5%.
Five, model case
Case 1: Yan * *, the man 63 years old now, lives piece Ge Dongping village, small stream township, Ziyuan County, Guangxi province Guilin, suffer from (acute) oedema due to nephritis in July, 1998, anasarca can not be walked, and can't start to walk, dyspnea, abdominal distention, oliguria, accept treatment after a while at county hospital, DeGrain, after take pill of the present invention, every day 1 time, each 1, every 9 gram, take medicine and took effect in back three days, fully recover after 9 days continue clothes pill of the present invention again, investigate so far not recurrence.
Case 2: woods *, man, 58 years old, live in that shuttle people from town of Guangxi province Fangcheng District, suffer from glomerulonephritis in July, 2006, because of failing to respond to any medical treatment, day increased the weight of then, looked into the right 150/110mmHg of blood pressure on April 7th, 2007, left side 160/110mmHg, anasarca, abdominal distention matter is hard, has obvious blue veins to expose, out of breath, cold limbs, pale purple dead color, defecate several days not down, oliguria does not have sometimes, it is poor to eat, diagnosis, edema, chronic glomerulonephritis, nephrotic syndrome uremia (renal failure), hepatitis B small three positive, cirrhotic ascites, liver inner bag official calculus belongs to critical illness, through clothes capsule of the present invention, after taking medicine 20 minutes in 1st, on tell a large amount of expectorant foams, defecation more than 20 time, sx after taking medicine two, recovery from illness in 15 days, existing alive.
Case 3: the king * *, the man 59 years old, lives in Ziyuan County, Guangxi piece Sha Ping people from village, small stream township, suffered from oedema due to nephritis (chronic cold disease) anasarca in 1998, dyspnea, the abdominal distention oliguria was accepted treatment at county hospital, DeGrain, took effect in 3rd through clothes granule of the present invention, recovery from illness after taking medicine 21 days is investigated and is not had recurrence so far.
Case 4: thunder * *, the woman 60 years old now, lives Ziyuan County, Guangxi piece Ge Dongping village, a small stream township inspection source group, suffered from oedema due to nephritis (chronic) anasarca in 1992, abdominal distention, out of breath, oliguria, accept treatment after a while at county hospital, DeGrain, the recovery from illness in 11 days of back clothes oral liquid of the present invention, not recurrence so far.
Following embodiment all can realize the effect of above-mentioned experimental example.
The specific embodiment
Embodiment 1:
A group: give birth to Fructus Crotonis 29kg Fructus Piperis 5kg Pericarpium Citri Reticulatae 5kg
Radix Aucklandiae 5kg Radix Glycyrrhizae 5kg Radix Achyranthis Bidentatae 30kg
B group: Radix Aconiti Lateralis Preparata 135kg Natrii Sulfas 25kg Radix Et Rhizoma Rhei 59kg
Concha Ostreae 100kg
C group: Rhizoma Atractylodis Macrocephalae 15kg Poria 45kg Cortex Cinnamomi 20kg
Radix Paeoniae Alba 10kg Rhizoma Zingiberis 40kg Polyporus 30kg
Herba Leonuri 30kg Rhizoma Imperatae 50kg Rhizoma Alismatis 50kg
Fructus Amomi 20kg Herba Pyrolae 40kg Rhizoma Zingiberis Recens 45kg
Ramulus Cinnamomi 20kg Radix Glycyrrhizae Preparata 5kg Radix Morindae Officinalis 20kg
Semen Cuscutae 20kg Herba Epimedii 20kg Fructus Amomi Rotundus 20kg
Radix Astragali 60kg Rhizoma Atractylodis 20kg Fructus Corni 100kg
Radix Angelicae Sinensis 30kg Pericarpium Arecae 30kg Cortex Magnoliae Officinalis 10kg
Herba Lysimachiae 30kg
A group, B group, C group medicine are ground into fine powder respectively, again with three groups of medicated powder mix homogeneously routinely technology add conventional adjuvant and make pill.Every day 1 time, each 1, every 9 gram.
Embodiment 2:
A group: give birth to Fructus Crotonis 20kg Fructus Piperis 6kg Pericarpium Citri Reticulatae 4kg
Radix Aucklandiae 6kg Radix Glycyrrhizae 4kg Radix Achyranthis Bidentatae 40kg
B group: Radix Aconiti Lateralis Preparata 100kg Natrii Sulfas 35kg Radix Et Rhizoma Rhei 40kg
Concha Ostreae 130kg
C group: Rhizoma Atractylodis Macrocephalae 10kg Poria 60kg Cortex Cinnamomi 15kg
Radix Paeoniae Alba 13kg Rhizoma Zingiberis 25kg Polyporus 40kg
Herba Leonuri 20kg Rhizoma Imperatae 70kg Rhizoma Alismatis 30kg
Fructus Amomi 25kg Herba Pyrolae 25kg Rhizoma Zingiberis Recens 55kg
Ramulus Cinnamomi 15kg Radix Glycyrrhizae 6kg Radix Morindae Officinalis 15kg
Semen Cuscutae 25kg Herba Epimedii 15kg Fructus Amomi Rotundus 25kg
Radix Astragali 40kg Rhizoma Atractylodis 25kg Fructus Corni 70kg
Radix Angelicae Sinensis 40kg Pericarpium Arecae 20kg Cortex Magnoliae Officinalis 13kg
Herba Lysimachiae 20kg
A group, B group, C group medicine are ground into fine powder respectively, again with three groups of medicated powder mix homogeneously routinely technology add conventional adjuvant and make capsule.
Embodiment 3:
A group: Fructus Crotonis 40kg Fructus Piperis 4kg Pericarpium Citri Reticulatae 6kg
Radix Aucklandiae 4kg Radix Glycyrrhizae 6kg Radix Achyranthis Bidentatae 20kg
B group: Radix Aconiti Lateralis Preparata 170kg Natrii Sulfas 15kg Radix Et Rhizoma Rhei 80kg
Concha Ostreae 70kg
C group: Rhizoma Atractylodis Macrocephalae 20kg Poria 30kg Cortex Cinnamomi 25kg
Radix Paeoniae Alba 7kg Rhizoma Zingiberis 55kg Polyporus 20kg
Herba Leonuri 40kg Rhizoma Imperatae 30kg Rhizoma Alismatis 70kg
Fructus Amomi 15kg Herba Pyrolae 55kg Rhizoma Zingiberis Recens 35kg
Ramulus Cinnamomi 25kg Radix Glycyrrhizae 3kg Radix Morindae Officinalis 25kg
Semen Cuscutae 15kg Herba Epimedii 25kg Fructus Amomi Rotundus 15kg
Radix Astragali 80kg Rhizoma Atractylodis 15kg Fructus Corni 130kg
Radix Angelicae Sinensis 20kg Pericarpium Arecae 40kg Cortex Magnoliae Officinalis 7kg
Herba Lysimachiae 40kg
Said medicine technology routinely adds conventional adjuvant and makes oral liquid.
Embodiment 4:
A group: Fructus Crotonis 29kg Fructus Piperis 19kg Pericarpium Citri Reticulatae 5kg
Radix Aucklandiae 5kg Radix Glycyrrhizae 5kg Radix Achyranthis Bidentatae 30kg
B group: Radix Aconiti Lateralis Preparata 135kg Natrii Sulfas 25kg Radix Et Rhizoma Rhei 59kg
Concha Ostreae 100kg
C group: Rhizoma Atractylodis Macrocephalae 15kg Poria 45kg Cortex Cinnamomi 20kg
Radix Paeoniae Alba 10kg Rhizoma Zingiberis 40kg Polyporus 30kg
Herba Leonuri 30kg Rhizoma Imperatae 50kg Rhizoma Alismatis 50kg
Fructus Amomi 20kg Herba Pyrolae 40kg Rhizoma Zingiberis Recens 45kg
Ramulus Cinnamomi 20kg Radix Glycyrrhizae 5kg Radix Morindae Officinalis 20kg
Semen Cuscutae 20kg Herba Epimedii 20kg Fructus Amomi Rotundus 20kg
Radix Astragali 60kg Rhizoma Atractylodis 20kg Fructus Corni 100kg
Radix Angelicae Sinensis 30kg Pericarpium Arecae 30kg Cortex Magnoliae Officinalis 10kg
Herba Lysimachiae 30kg
Said medicine technology routinely adds conventional adjuvant and makes drop pill.

Claims (8)

1. pharmaceutical composition for the treatment of nephritis is characterized in that the crude drug of said composition consists of:
A group: give birth to Fructus Crotonis 15-45 weight portion Fructus Piperis 3-7 weight portion Pericarpium Citri Reticulatae 3-7 weight portion
Radix Aucklandiae 3-7 weight portion Radix Glycyrrhizae 3-7 weight portion Radix Achyranthis Bidentatae 15-45 weight portion;
B group: Radix Aconiti Lateralis Preparata 70-200 weight portion Natrii Sulfas 12-38 weight portion Radix Et Rhizoma Rhei 30-90 weight portion
Concha Ostreae 50-150 weight portion;
C group: Rhizoma Atractylodis Macrocephalae 7-23 weight portion Poria 25-65 weight portion Cortex Cinnamomi 10-30 weight portion
Radix Paeoniae Alba 5-15 weight portion Rhizoma Zingiberis 20-60 weight portion Polyporus 15-45 weight portion
Herba Leonuri 15-45 weight portion Rhizoma Imperatae 25-75 weight portion Rhizoma Alismatis 25-75 weight portion
Fructus Amomi 10-30 weight portion Herba Pyrolae 20-60 weight portion Rhizoma Zingiberis Recens 30-60 weight portion
Ramulus Cinnamomi 10-30 weight portion Radix Glycyrrhizae 2-8 weight portion Radix Morindae Officinalis 10-30 weight portion
Semen Cuscutae 10-30 weight portion Herba Epimedii 10-30 weight portion Fructus Amomi Rotundus 10-30 weight portion
Radix Astragali 30-90 weight portion Rhizoma Atractylodis 10-30 weight portion Fructus Corni 50-150 weight portion
Radix Angelicae Sinensis 15-45 weight portion Pericarpium Arecae 15-45 weight portion Cortex Magnoliae Officinalis 5-15 weight portion
Herba Lysimachiae 15-45 weight portion.
2. pharmaceutical composition according to claim 1 is characterized in that the crude drug of said composition
Consist of:
A group: give birth to Fructus Crotonis 29 weight portion Fructus Piperiss 5 weight portion Pericarpium Citri Reticulataes 5 weight portions
The Radix Aucklandiae 5 weight portion Radix Glycyrrhizae 5 weight portion Radix Achyranthis Bidentataes 30 weight portions;
B group: Radix Aconiti Lateralis Preparata 135 weight portion Natrii Sulfas 25 weight portion Radix Et Rhizoma Rhei 59 weight portions
Concha Ostreae 100 weight portions;
C group: the Rhizoma Atractylodis Macrocephalae 15 weight portion Poria 45 weight portion Cortex Cinnamomis 20 weight portions
The Radix Paeoniae Alba 10 weight portion Rhizoma Zingiberiss 40 weight portion Polyporus 30 weight portions
Herba Leonuri 30 weight portion Rhizoma Imperataes 50 weight portion Rhizoma Alismatis 50 weight portions
Fructus Amomi 20 weight portion Herba Pyrolaes 40 weight portion Rhizoma Zingiberis Recenss 45 weight portions
Ramulus Cinnamomi 20 weight portion Radix Glycyrrhizae 5 weight portion Radix Morindae Officinaliss 20 weight portions
Semen Cuscutae 20 weight portion Herba Epimedii 20 weight portion Fructus Amomi Rotunduss 20 weight portions
The Radix Astragali 60 weight portion Rhizoma Atractylodis 20 weight portion Fructus Corni 100 weight portions
Radix Angelicae Sinensis 30 weight portion Pericarpium Arecae 30 weight portion Cortex Magnoliae Officinalis 10 weight portions
Herba Lysimachiae 30 weight portions.
3. pharmaceutical composition according to claim 1 is characterized in that the crude drug of said composition consists of:
A group: give birth to Fructus Crotonis 20 weight portion Fructus Piperiss 6 weight portion Pericarpium Citri Reticulataes 4 weight portions
The Radix Aucklandiae 6 weight portion Radix Glycyrrhizae 4 weight portion Radix Achyranthis Bidentataes 40 weight portions;
B group: Radix Aconiti Lateralis Preparata 100 weight portion Natrii Sulfas 35 weight portion Radix Et Rhizoma Rhei 40 weight portions
Concha Ostreae 130 weight portions;
C group: the Rhizoma Atractylodis Macrocephalae 10 weight portion Poria 60 weight portion Cortex Cinnamomis 15 weight portions
The Radix Paeoniae Alba 13 weight portion Rhizoma Zingiberiss 25 weight portion Polyporus 40 weight portions
Herba Leonuri 20 weight portion Rhizoma Imperataes 70 weight portion Rhizoma Alismatis 30 weight portions
Fructus Amomi 25 weight portion Herba Pyrolaes 25 weight portion Rhizoma Zingiberis Recenss 55 weight portions
Ramulus Cinnamomi 15 weight portion Radix Glycyrrhizae 6 weight portion Radix Morindae Officinaliss 15 weight portions
Semen Cuscutae 25 weight portion Herba Epimedii 15 weight portion Fructus Amomi Rotunduss 25 weight portions
The Radix Astragali 40 weight portion Rhizoma Atractylodis 25 weight portion Fructus Corni 70 weight portions
Radix Angelicae Sinensis 40 weight portion Pericarpium Arecae 20 weight portion Cortex Magnoliae Officinalis 13 weight portions
Herba Lysimachiae 20 weight portions.
4. pharmaceutical composition according to claim 1 is characterized in that the crude drug of said composition consists of:
A group: give birth to Fructus Crotonis 40 weight portion Fructus Piperiss 4 weight portion Pericarpium Citri Reticulataes 6 weight portions
The Radix Aucklandiae 4 weight portion Radix Glycyrrhizae 6 weight portion Radix Achyranthis Bidentataes 20 weight portions;
B group: Radix Aconiti Lateralis Preparata 170 weight portion Natrii Sulfas 15 weight portion Radix Et Rhizoma Rhei 80 weight portions
Concha Ostreae 70 weight portions;
C group: the Rhizoma Atractylodis Macrocephalae 20 weight portion Poria 30 weight portion Cortex Cinnamomis 25 weight portions
The Radix Paeoniae Alba 7 weight portion Rhizoma Zingiberiss 55 weight portion Polyporus 20 weight portions
Herba Leonuri 40 weight portion Rhizoma Imperataes 30 weight portion Rhizoma Alismatis 70 weight portions
Fructus Amomi 15 weight portion Herba Pyrolaes 55 weight portion Rhizoma Zingiberis Recenss 35 weight portions
Ramulus Cinnamomi 25 weight portion Radix Glycyrrhizae 3 weight portion Radix Morindae Officinaliss 25 weight portions
Semen Cuscutae 15 weight portion Herba Epimedii 25 weight portion Fructus Amomi Rotunduss 15 weight portions
The Radix Astragali 80 weight portion Rhizoma Atractylodis 15 weight portion Fructus Corni 130 weight portions
Radix Angelicae Sinensis 20 weight portion Pericarpium Arecae 40 weight portion Cortex Magnoliae Officinalis 7 weight portions
Herba Lysimachiae 40 weight portions.
5. according to the described pharmaceutical composition of one of claim 1-4, it is characterized in that said composition adds the dosage form that conventional adjuvant is made clinical acceptance by practice of pharmacy.
6. pharmaceutical composition according to claim 5 is characterized in that described dosage form is tablet, capsule, granule, pill, oral liquid or lyophilized powder.
7. pharmaceutical composition according to claim 5 is characterized in that described dosage form is a drop pill.
8. according to the application of the described pharmaceutical composition of one of claim 1-4 in the medicine of preparation treatment nephritis.
CN2007101205085A 2007-08-20 2007-08-20 Medicine composition for treating nephropathy and uses of the same Expired - Fee Related CN101130030B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2007101205085A CN101130030B (en) 2007-08-20 2007-08-20 Medicine composition for treating nephropathy and uses of the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007101205085A CN101130030B (en) 2007-08-20 2007-08-20 Medicine composition for treating nephropathy and uses of the same

Publications (2)

Publication Number Publication Date
CN101130030A CN101130030A (en) 2008-02-27
CN101130030B true CN101130030B (en) 2010-11-17

Family

ID=39127542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007101205085A Expired - Fee Related CN101130030B (en) 2007-08-20 2007-08-20 Medicine composition for treating nephropathy and uses of the same

Country Status (1)

Country Link
CN (1) CN101130030B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988943A (en) * 2012-11-22 2013-03-27 林红丽 Traditional Chinese medicine for treating chronic nephritis
CN103656299B (en) * 2013-12-16 2016-01-06 卞佳林 A kind of Chinese medicine preparation for the treatment of chronic glomerulonephritis

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101485872B (en) * 2009-03-06 2011-11-30 大连美罗中药厂有限公司 Chinese medicinal composition for treating gastropathy as well as preparation and detection method thereof
CN102100902B (en) * 2011-02-15 2012-03-28 江西本草天工科技有限责任公司 Counterflow effervescent tablets
CN102614445A (en) * 2012-02-21 2012-08-01 简福川 Herbal medicine for treating chronic pyelonephritis
CN102552865B (en) * 2012-03-06 2013-11-06 崔淑云 Traditional Chinese medicine composition for treating gestational edema
CN102813895B (en) * 2012-08-03 2014-01-01 王玉英 Preparation method of traditional Chinese medicine for treating somnolence-type acute glomerulonephritis
CN102861314B (en) * 2012-10-28 2014-06-11 牛健坤 Medicine for treating nephropathy and preparation method thereof
CN102961707B (en) * 2012-11-26 2014-04-30 王祥生 Traditional Chinese medicine for treating chronic renal failure
CN103385991B (en) * 2013-08-15 2015-01-14 江西中成药业集团有限公司 Radix stephaniae tetrandrae mixture for veterinary use and preparation method thereof
CN103431260B (en) * 2013-08-31 2014-08-20 山东卫康生物医药科技有限公司 Mixed-grain full-nutrition formulation food for patients with gastrointestinal tract malabsorption and pancreatitis
CN103566118B (en) * 2013-11-30 2015-07-29 张晓莉 A kind of medicine and preparation method for the treatment of chronic nephritis
CN103830511B (en) * 2014-03-05 2016-03-23 苏文德 A kind of Chinese medicine preparation eliminating Foreskin edema
CN103816525B (en) * 2014-03-21 2016-06-29 山东大学齐鲁医院 A kind of part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels weakened YANG QI for the treatment of causes the Chinese medicine composition of dysuria
CN104043080B (en) * 2014-06-13 2016-07-13 陈镇刚 Chinese medicine composition for the treatment of nephritis and preparation method thereof
CN104288543A (en) * 2014-08-19 2015-01-21 肖仕琼 Frequently-drank tea-substituting traditional Chinese medicine preparation for treating kidney diseases
CN104288662A (en) * 2014-10-28 2015-01-21 禤燕华 Traditional Chinese medicine composition for treating nephritic proteinuria
CN104771607A (en) * 2015-01-27 2015-07-15 刘卓韬 Traditional Chinese medicinal composition and acupoint combination acupuncture application for treating nephritis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184658A (en) * 1997-07-09 1998-06-17 迟经惠 Pill for invigorating liver and kidney
CN1651048A (en) * 2001-11-18 2005-08-10 孙燕明 Chinese medicinal preparation for treating pelvis nephritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184658A (en) * 1997-07-09 1998-06-17 迟经惠 Pill for invigorating liver and kidney
CN1651048A (en) * 2001-11-18 2005-08-10 孙燕明 Chinese medicinal preparation for treating pelvis nephritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
靳育民.温肾补阳法治疗慢性肾小球肾炎135例.陕西中医15 10.1994,15(10),第441页.
靳育民.温肾补阳法治疗慢性肾小球肾炎135例.陕西中医15 10.1994,15(10),第441页. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988943A (en) * 2012-11-22 2013-03-27 林红丽 Traditional Chinese medicine for treating chronic nephritis
CN103656299B (en) * 2013-12-16 2016-01-06 卞佳林 A kind of Chinese medicine preparation for the treatment of chronic glomerulonephritis

Also Published As

Publication number Publication date
CN101130030A (en) 2008-02-27

Similar Documents

Publication Publication Date Title
CN101130030B (en) Medicine composition for treating nephropathy and uses of the same
CN101766802B (en) Chinese medicine composite for treatment of acute gastroenteritis and preparation method thereof
CN101642535B (en) Medicinal composition for treating gout
CN102772778B (en) Traditional Chinese medicine composition for treating summer heat-dampness
CN101972443B (en) Chinese medicinal formula for treating chronic gastritis
CN102008655B (en) Traditional Chinese medicine composition for treating arthralgia and preparation method thereof
CN100478020C (en) Stomatocase treating medicine
CN101396548A (en) Medicine composition for treating chronic gastritis
CN1977959A (en) Chinese medicine compound preparation for comprehensively regulating body function and its preparing method
CN102058784A (en) Medicinal composition for treating pulmonary heart disease and application thereof
CN101897879B (en) Traditional Chinese medicine for treating rheumatic arthritis
CN101912567B (en) Chinese medicinal prescription for treating chronic myocarditis
CN101664524A (en) Medicament for treating paranasal sinusitis and preparation method thereof
CN103127351B (en) Traditional Chinese medicine for treating premature menstruation
CN105395911A (en) Traditional Chinese medicine for curing cerebral thrombosis
CN102698024B (en) Oral traditional Chinese medicine preparation for treating postoperative intestinal adhesion
CN102210839A (en) Traditional Chinese medicine capsule for treating coronary heart disease
CN104189368A (en) Traditional Chinese medicinal composition for treating spleen and stomach diseases and preparation method thereof
CN103721082A (en) Traditional Chinese medicinal composition for treating scapulohumeral periarthritis
CN104173727A (en) Medicine for treating toothache
CN103656453A (en) Semen litchi stomach-nourishing condensed pill and preparation method thereof
CN104337994A (en) Medicine for treating digestive tract cancers
CN102698130B (en) Traditional Chinese medicine extract for treating postoperative intestinal adhesion
CN101721653A (en) Traditional Chinese medicine for treating hyperthyroidism
CN104873911A (en) Traditional Chinese medicine for oral administration for adjunctively treating sepsis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101117

Termination date: 20140820

EXPY Termination of patent right or utility model